Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialAndrew J Armstrong, Susan Halabi, Tim Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell CarcinomaAndrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Oncotarget|February 11, 2017
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer studyNilofer S Azad, Anthony El-Khoueiry, Jun Yin, et al.
Kidney Cancer Journal : Official Journal of the Kidney Cancer Association|November 12, 2021
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trialSusan Halabi, Qian Yang, Andrea Carmack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
British Journal of Cancer|May 17, 2018
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)Jonathan E Rosenberg, Noah M Hahn, Meredith M Regan, et al.
The Journal of Urology|April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot studyAdam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.
Clinical and Translational Radiation Oncology|January 19, 2019
A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer DatabaseBenjamin W Fischer-Valuck, Jeff M Michalski, Jessika A Contreras, et al.
Clinical Genitourinary Cancer|November 14, 2020
Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent ChemoradiotherapyBenjamin W Fischer-Valuck, Jeff M Michalski, Joanna G Harton, et al.
Pageof 10